MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

Br J Haematol. 2015 Nov;171(3):432-5. doi: 10.1111/bjh.13411. Epub 2015 Apr 8.

¹ Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA. [email protected].
² Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
³ Translational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
⁴ Division of Biostatistics, Departments of Population Health, New York University School of Medicine, New York, NY, USA.
⁵ Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
⁶ Informatics, Roche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, NY, USA.
⁷ Biometrics, Product Development, Roche Innovation Center New York, New York, NY, USA.
⁸ Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
⁹ Discovery Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
¹⁰ Translational Medicine Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.

No abstract available

Keywords: MDM2 antagonist; TP53; acute myeloid leukaemia; diagnostic algorithm; gene expression signature.

Publication types